The potential role of appetite in predicting weight changes during treatment with olanzapine

Case, Michael; Treuer, Tamas; Karagianis, Jamie; Hoffmann, Vicki Poole
January 2010
BMC Psychiatry;2010, Vol. 10, p72
Academic Journal
Background: Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite. Methods: Data were used from adult patients for whom both appetite and weight data were available from 4 prospective, 12- to 24-week clinical trials. Patients' appetites were assessed with Eating Behavior Assessment (EBA, Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI, Study 3), and Eating Attitude Scale (EAS, Study 4). Results: In Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI), patients who reported overall score increases on appetite scales did not experience greater weight changes than patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional information was gained by adding early appetite change to early weight change in correlation to overall weight change. Conclusions: Early weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales. Clinical Trials Registration: This report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were registered at http://clinicaltrials.gov/ct2/home, under NCT00190749, NCT00303602, and NCT00401973, respectively. Study 4 predates the registration requirements for observational studies that are not classified as category 1 observational studies.


Related Articles

  • Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Togo, Takashi; Hasegawa, Koichi; Miura, Satoshi; Hosojima, Hideki; Kojima, Katsuo; Shoji, Mika; Kase, Akihiko; Uchikado, Hirotake; Iseki, Eizo; Kosaka, Kenji // Psychopharmacology;2004, Vol. 172 Issue 2, p230 

    Rationale. Although enhanced appetite and weight gain are potential side effects of treatment with antipsychotic agents, particularly olanzapine and clozapine, the mechanism is poorly understood. Objectives. To test the hypothesis that ghrelin, a gastrointestinal hormone that enhances appetite,...

  • Appetite Regulation: Hormones and Antipsychotics. Robinson, Donald S. // Primary Psychiatry;Feb2008, Vol. 15 Issue 2, p24 

    The article investigates the effects of antipsychotic therapy on appetite. It is noted that antipsychotics such as clozapine and olanzapine are prone to produce excessive weight gain. The effects of hormones ghrelin and leptin on appetite and weight control is discussed. It says first-generation...

  • The Association of Olanzapine-Induced Weight Gain with Peroxisome Proliferator�Activated Receptor-?2 Pro12Ala Polymorphism in Patients with Schizophrenia. Herken, Hasan; Erdal, Mehmet; Aydin, Nazan; Sengul, Cem; Karadag, Filiz; Barlas, Omer; Akin, Fulya // DNA & Cell Biology;Oct2009, Vol. 28 Issue 10, p515 

    Olanzapine is a second-generation antipsychotic that may cause weight gain and metabolic syndrome in some cases. The peroxisome proliferator�activated receptor ( PPAR)-? is an important gene in the progress of type II diabetes and metabolic syndrome. In recent studies the polymorphism of...

  • Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation. Fernø, Johan; Varela, Luis; Skrede, Silje; Vázquez, María Jesús; Nogueiras, Rubén; Diéguez, Carlos; Vidal-Puig, Antonio; Steen, Vidar M.; López, Miguel // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    The success of antipsychotic drug treatment in patients with schizophrenia is limited by the propensity of these drugs to induce hyperphagia, weight gain and other metabolic disturbances, particularly evident for olanzapine and clozapine. However, the molecular mechanisms involved in...

  • Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. Detke, Holland C.; McDonnell, David P.; Brunner, Elizabeth; Fangyi Zhao; Sorsaburu, Sebastian; Stefaniak, Victoria J.; Corya, Sara A. // BMC Psychiatry;2010, Vol. 10, p43 

    Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation...

  • No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs. Cope, M. B.; Jumbo-Lucioni, P.; Walton, R. G.; Kesterson, R. A.; Allison, D. B.; Nagy, T. R. // International Journal of Obesity;Jun2007, Vol. 31 Issue 6, p1014 

    Rationale:Atypical antipsychotic drugs (AAD) induce significant weight gain in female C57BL/6J mice. The effect of dietary fat on weight gain and serum lipids in this model is unknown.Objectives:Test the hypothesis that the obesigenic effects of these drugs are greater in the presence of a...

  • Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Kalinichev, Mikhail; Rourke, Claire; Daniels, Alex J.; Grizzle, Mary K.; Britt, Christy S.; Ignar, Diane M.; Jones, Declan N. C. // Psychopharmacology;Oct2005, Vol. 182 Issue 2, p220 

    Rationale: Atypical antipsychotic drug (APD)- induced weight gain causes non-compliance, increasing the risk of relapse and medical complications. Objectives: In an animal model, we assessed body weights, food intake, body fat/lean body mass contents and blood serum levels of glucose and lipids...

  • Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Kirk, Shona L.; Glazebrook, John; Grayson, Ben; Neill, Joanna C.; Reynolds, Gavin P. // Psychopharmacology;Nov2009, Vol. 207 Issue 1, p119 

    Substantial increases in body weight can be induced by several antipsychotic drugs, most notably olanzapine and clozapine. Antagonism at certain receptors, particularly 5-HT2C and histamine H1 receptors, is implicated in this effect. We have investigated the contribution of effects at these...

  • Olanzapine.  // Reactions Weekly;5/20/2006, Issue 1102, p11 

    Discusses research on extensive weight loss in a patient with schizophrenia after switching from olanzepine to aripiprazole. Reference to a study by S. Kropp and colleagues, published in the March 2006 issue of "Pharmacopsychiatry"; Weight gain developed during treatment with olanzapine and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics